**INTRODUCTION**

Abrocitinib is an oral, once-daily, Janus kinase (JAK) inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adolescents and adults in the United States. This analysis included adolescents and adults with moderate-to-severe AD who enrolled in the ongoing phase 3 extension trial JADE EXTEND (NCT03422822).

**OBJECTIVE**

To assess abrocitinib treatment efficacy up to 96 weeks in adolescents and adults with moderate-to-severe AD who enrolled in the ongoing phase 3 extension trial JADE EXTEND (NCT03422822).

**METHODS**

This interim analysis included adolescents (aged 12 to 17 years) and adult (aged 18 years and older) patients from qualifying parent phase 3 JADE trials who subsequently enrolled in the ongoing JADE EXTEND trial. BASELINE PROPORTIONS OF PATIENTS WITH MODERATE-TO-SEVERE AD AT ENROLLMENT IN JADE EXTEND: BASELINE PROPORTIONS OF PATIENTS WITH MODERATE-TO-SEVERE AD AT ENROLLMENT IN JADE EXTEND: Adolescents

<table>
<thead>
<tr>
<th>Proportion of Patients</th>
<th>Adolescents 100 mg QD</th>
<th>Adolescents 200 mg QD</th>
<th>Adults 100 mg QD</th>
<th>Adults 200 mg QD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion of Patients</td>
<td>Adolescents 100 mg QD</td>
<td>Adolescents 200 mg QD</td>
<td>Adults 100 mg QD</td>
<td>Adults 200 mg QD</td>
</tr>
<tr>
<td>Proportion of Patients</td>
<td>PP-NRS 0/1</td>
<td>PP-NRS 0/1</td>
<td>PP-NRS 0/1</td>
<td>PP-NRS 0/1</td>
</tr>
<tr>
<td>Proportion of Patients</td>
<td>IGA 0/1</td>
<td>IGA 0/1</td>
<td>IGA 0/1</td>
<td>IGA 0/1</td>
</tr>
</tbody>
</table>

**RESULTS**

- Baseline disease characteristics were largely comparable across both patient groups (Supplementary Table 5).
- Adolescents tended to have more severe disease than adult patients at baseline.
- Dose-dependent efficacy was observed for both adolescents and adults over the duration of treatment, up to 96 weeks for both adolescent and adult groups.

**CONCLUSIONS**

- The proportions of responders were largely comparable for both doses at week 96.
- Baseline disease characteristics were largely comparable across both patient groups.
- This analysis included 357 adolescent and 1309 adult patients.

**ACKNOWLEDGMENTS**

Amy S. Paller,1 Michael J. Cork,2 Carsten Flohr,3 Christine Bangert,4 Stephan Weidinger,5 John Nesnas,6

1. Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; 2. Sheffield Dermatology Research, ICD; 3. University of Sheffield and Sheffield Children’s Hospital, Sheffield, UK; 4. University of Sheffield; 5. University of Sheffield and Sheffield Children’s Hospital, Sheffield, South Yorkshire, UK; 6. Pfizer Inc., New York, NY, USA; 7. Pfizer Corporation Austria GmbH, Vienna, Austria.

**REFERENCES**


**DISCLOSURES**

- Amy S. Paller is an employee of Pfizer, Inc., and owns stock in the company.
- Michael J. Cork is an employee of Pfizer, Inc., and owns stock in the company.
- Carsten Flohr has reported grants from Sanofi Deutschland GmbH, Leo Pharma, and La Roche-Posay; has performed consultancies for Sanofi-Genzyme, Regeneron, LEO Pharma, AbbVie, Pfizer, Eli Lilly, Kymab, and Novartis; has lectured at educational events sponsored by Astellas, Galderma, BioCryst, BiomX, Bridgebio, Bristol Myers Squibb, Castle Biosciences, Catawba, Eli Lilly, Exicure, Gilead, Genentech, Genzyme, GlaxoSmithKline, Galapagos, Hyphens, Johnson & Johnson, Kamari, Leo, Novartis, OM Pharma, Pierre Fabre, RAPT, Regeneron, Sanofi/Genzyme, and Sanofi Deutschland GmbH.

- Othout is on the editorial boards of British Journal of Dermatology and Journal of Investigative Dermatology.

- Please visit the Disclosure forms for full details.

**COPYRIGHT © 2023. All rights reserved.**